Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients
Retrospective study indicates consolidation and maintenance strategies yield similar progression-free survival in PCNSL patients.
Key Points
Median overall survival in patients receiving consolidation therapy was 95 months, with progression-free survival at 62 months.
Clinical data from 191 transplant-ineligible patients were analyzed, showing better outcomes than previously expected from induction therapy.
Induction regimens included high-dose methotrexate, procarbazine, and rituximab in various combinations leading to different post-induction strategies.
Worse overall survival correlated significantly with lack of complete response and poor ECOG performance status after induction therapy.